ES2772802T3 - Composiciones y procedimientos para tratar la hemorragia intracerebral - Google Patents

Composiciones y procedimientos para tratar la hemorragia intracerebral Download PDF

Info

Publication number
ES2772802T3
ES2772802T3 ES15708578T ES15708578T ES2772802T3 ES 2772802 T3 ES2772802 T3 ES 2772802T3 ES 15708578 T ES15708578 T ES 15708578T ES 15708578 T ES15708578 T ES 15708578T ES 2772802 T3 ES2772802 T3 ES 2772802T3
Authority
ES
Spain
Prior art keywords
less
ich
fxa
variant
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15708578T
Other languages
English (en)
Spanish (es)
Inventor
Steven Arkin
Joachim Fruebis
Marcus E Carr
Sunita Hett
Reema Jasuja
Debra D Pittman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2772802T3 publication Critical patent/ES2772802T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES15708578T 2014-01-24 2015-01-15 Composiciones y procedimientos para tratar la hemorragia intracerebral Active ES2772802T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Publications (1)

Publication Number Publication Date
ES2772802T3 true ES2772802T3 (es) 2020-07-08

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15708578T Active ES2772802T3 (es) 2014-01-24 2015-01-15 Composiciones y procedimientos para tratar la hemorragia intracerebral

Country Status (18)

Country Link
US (2) US20160375109A1 (enExample)
EP (1) EP3096779B1 (enExample)
JP (1) JP6624787B2 (enExample)
KR (3) KR20160093731A (enExample)
CN (2) CN105934250A (enExample)
AU (1) AU2015208819B2 (enExample)
BR (1) BR112016014617A2 (enExample)
CA (1) CA2937418A1 (enExample)
DK (1) DK3096779T3 (enExample)
ES (1) ES2772802T3 (enExample)
HU (1) HUE047588T4 (enExample)
IL (1) IL246637A0 (enExample)
MX (1) MX375355B (enExample)
PL (1) PL3096779T3 (enExample)
PT (1) PT3096779T (enExample)
RU (1) RU2016126423A (enExample)
SI (1) SI3096779T1 (enExample)
WO (1) WO2015110939A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
CN112195169A (zh) 2013-09-24 2021-01-08 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
KR20260076240A (ko) 2024-11-18 2026-05-28 한림대학교 산학협력단 뇌내출혈 질환 진단용 rs5117 마커 조성물 및 이의 용도
KR20260076239A (ko) 2024-11-18 2026-05-28 한림대학교 산학협력단 뇌내출혈 질환 진단용 rs429358 마커 조성물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06015045A (es) * 2004-06-21 2007-03-21 Novo Nordisk Healthcare Ag Uso del factor viia o equivalentes del factor viia para prevenir o atenuar el crecimiento de hemorragias y/o generacion de edemas despues de una hemorragia intracerebral.
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
JP2011509978A (ja) * 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
EP2453910B1 (en) * 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
EP2467166A2 (en) * 2009-08-20 2012-06-27 CSL Behring GmbH Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
KR102049900B1 (ko) * 2012-07-25 2019-11-28 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 인자 x 폴리펩티드 및 이의 용도
HK1215196A1 (zh) * 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法

Also Published As

Publication number Publication date
DK3096779T3 (da) 2020-02-24
BR112016014617A2 (pt) 2017-09-19
JP6624787B2 (ja) 2019-12-25
MX375355B (es) 2025-03-04
SI3096779T1 (sl) 2020-03-31
CN105934250A (zh) 2016-09-07
HUE047588T2 (hu) 2020-04-28
AU2015208819A1 (en) 2016-06-30
PT3096779T (pt) 2020-02-21
WO2015110939A1 (en) 2015-07-30
EP3096779B1 (en) 2019-12-18
US20160375109A1 (en) 2016-12-29
HUE047588T4 (hu) 2020-06-29
JP2015147764A (ja) 2015-08-20
US20190231856A1 (en) 2019-08-01
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
IL246637A0 (en) 2016-08-31
RU2016126423A3 (enExample) 2018-03-01
EP3096779A1 (en) 2016-11-30
KR20180014221A (ko) 2018-02-07
CN112156176A (zh) 2021-01-01
KR20160093731A (ko) 2016-08-08
MX2016009665A (es) 2016-11-14
CA2937418A1 (en) 2015-07-30
RU2016126423A (ru) 2018-03-01
AU2015208819B2 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
JP6998333B2 (ja) Ａｄａｍｔｓ１３の皮下投与
ES2761730T3 (es) Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
JP6741642B2 (ja) くも膜下出血および虚血の治療法
Zhou et al. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura
US20090117099A1 (en) Extracellular histones as biomarkers for prognosis and molecular targets for therapy
US10493135B2 (en) Methods of treating tissue calcification
US20190231856A1 (en) Compositions and methods for treating intracerebral hemorrhage
ES2823998T3 (es) Nuevos activadores de plasminógeno tisular mutados y usos de los mismos
JP2017502036A (ja) 血友病の予防的処置のための第ｉｘ因子を含む融合タンパク質およびその方法
JP6629744B2 (ja) 第Ｘａ因子の半減期を延ばす組成物および方法
EP3420087B1 (en) Peptide-based methods for treating neurological injury
HK40040435A (en) Compositions and methods for treating intracerebral hemorrhage
HK1228257A1 (en) Compositions and methods for treating intracerebral hemorrhage
WO2026076443A1 (en) Methods for treating factor x deficiency
ES2963665T3 (es) Régimen de dosificación de 21 días para proteínas de fusión que comprenden factor ix y albúmina humana para el tratamiento profiláctico de la hemofilia y procedimientos para ello
WO2020084853A1 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬